Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4427642 | 0.98 | KDM1A (0.50) | KDM1AMEN1KMT2AAKR1B1MAOB | |
| SCHEMBL2465794 | 0.89 | KDM1A (0.46) | KDM1AMEN1KMT2AMAOBSIGMAR1 | |
| SCHEMBL7445452 | 0.89 | KDM1A (0.46) | KDM1AMEN1KMT2AMAOBSIGMAR1 | |
| SCHEMBL4862191 | 0.75 | MEN1 (0.53) | KDM1AMEN1KMT2AAKR1B1SIGMAR1 | |
| SCHEMBL1101137 | 0.75 | KDM1A (0.59) | KDM1AMEN1KMT2AAKR1B1MAOB | |
| SCHEMBL30112838 | 0.75 | KDM1A (0.59) | KDM1AMEN1KMT2AAKR1B1MAOB | |
| SCHEMBL2091146 | 0.72 | KDM1A (0.45) | KDM1AMEN1KMT2AAKR1B1MAOB | |
| SCHEMBL643388 | 0.72 | KDM1A (0.66) | KDM1AMEN1KMT2AAKR1B1MAOB | |
| SCHEMBL9396129 | 0.72 | KDM1A (0.56) | KDM1AMEN1KMT2AAKR1B1MAOB | |
| SCHEMBL6440070 | 0.72 | KDM1A (0.56) | KDM1AMEN1KMT2AAKR1B1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100422181-C | [1,8] naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-1839134-A | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2006-09-27 | — | — | CN | disclosed |
| US-6881753-B2 | Potassium channel inhibitors and method | BRISTOL-MYERS SQUIBB CO. (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1109544-A4 | POTASSIUM CHANNEL INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040192710-A1 | Potassium channel inhibitors and method | LLOYD JOHN (US) | 2004-09-30 | — | — | US | disclosed |
| US-6784189-B2 | SULFONAMIDE COMPOUNDS CONTAINING BICYCLIC RING STRUCTURE ARE USEFUL AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040067944-A1 | Potassium channel inhibitors and method | LLOYD JOHN (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040058931-A1 | Potassium channel inhibitors and method | LLOYD JOHN (US) | 2004-03-25 | — | — | US | disclosed |
| US-6511977-B1 | For preventing or treating cardiac arrhythmia or atrial arrhythmia | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-28 | — | — | US | disclosed |
| EP-1109544-A1 | POTASSIUM CHANNEL INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6150356-A | BENZOPYRANS AND DERIVATIVES ARE USED AS POTASSIUM CHANNEL INHIBITORS AND THUS ARE USEFUL AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000012077-A1 | POTASSIUM CHANNEL INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-09 | — | — | WO | disclosed |
| EP-0272534-A2 | 8-substituted 2-aminotetralins | BAYER AG (DE) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058931-A1 | Potassium channel inhibitors and method | KCNH2, KCNJ2, KCNB1 | KDM1A 516/4885MEN1 3529/4885KMT2A 1569/4885 |
| US-20040192710-A1 | Potassium channel inhibitors and method | KCNH2, KCNJ2, KCNB1 | KDM1A 516/4885MEN1 3529/4885KMT2A 1569/4885 |
| US-20040067944-A1 | Potassium channel inhibitors and method | KCNH2, KCNJ2, KCNB1 | KDM1A 516/4885MEN1 3529/4885KMT2A 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.